ViVerita Therapeutics licenses CRISPR-StAR patent from IMBA

ViVerita announces to having executed a licensing deal for CRISPR-StAR and CRISPR-Switch, two proprietary technologies developed by ViVeritas founder Dr. Elling as principal investigator at the Institute of Molecular Biotechnology (IMBA) of the Austrian Academy of Sciences (OEAW).

These technologies will enable ViVerita to discover new high-value targets foremost for precision oncology.